Effect of L Carnitine on severity of uremic restless legs syndrome

Study the effect of treatment with L Carnitine on severity of uremic restless legs syndrome in dialysis patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N171

Enrollment

Registered

2021-07-04

Start date

2021-05-21

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Restless leg syndrome. Restless legs syndrome

Interventions

Intervention 1: The intervention group will receive 500 mg of L-carnitine tablets (Behta) daily, every 12 hours for three months. Intervention 2: The control group will receive a 500 mg daily placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Dialysis patients with restless legs syndrome Patient informed consent

Exclusion criteria

Exclusion criteria: Patients diagnosed with anxiety disorders Patients with a diagnosis of sleep disorders

Design outcomes

Primary

Measure	Time frame
Severity of Restless Legs Syndrome. Timepoint: Beginning of treatment, sixth week and end of treatment (three months later). Method of measurement: Based on clinical observation, physician and patient opinion.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahnaz Khosravi

Kermanshah University of Medical Sciences

mahnazkhosravi141167@gmail.com+98 83 3427 6306

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026